Study: NCT01314872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron
Description: Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: Participants received one tolterodine ER 4 mg capsule, taken orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching vibegron
Description: Participants received placebo matching vibegron tablets, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tolterodine ER
Description: Participants received placebo matching tolterodine ER capsule, taken orally each morning.